These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34329486)

  • 1. A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine.
    Messali S; Bertelli A; Campisi G; Zani A; Ciccozzi M; Caruso A; Caccuri F
    J Med Virol; 2021 Dec; 93(12):6468-6470. PubMed ID: 34329486
    [No Abstract]   [Full Text] [Related]  

  • 2. Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients.
    Valleriani F; Mancuso E; Vincifori G; Teodori L; Di Marcantonio L; Spedicato M; Leone A; Savini G; Morelli D; Bonfini B; Lorusso A
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
    Wang Y
    EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
    [No Abstract]   [Full Text] [Related]  

  • 4. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
    Zani A; Caccuri F; Messali S; Bonfanti C; Caruso A
    Emerg Microbes Infect; 2021 Dec; 10(1):1241-1243. PubMed ID: 34092181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
    Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Bagratuni T; Papanagnou ED; Patseas D; Gumeni S; Malandrakis P; Korompoki E; Dimopoulos MA
    Am J Hematol; 2021 Sep; 96(9):E321-E324. PubMed ID: 34028867
    [No Abstract]   [Full Text] [Related]  

  • 6. Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2.
    Lustig Y; Nemet I; Kliker L; Zuckerman N; Yishai R; Alroy-Preis S; Mendelson E; Mandelboim M
    N Engl J Med; 2021 Jun; 384(25):2453-2454. PubMed ID: 33826815
    [No Abstract]   [Full Text] [Related]  

  • 7. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
    Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
    J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
    [No Abstract]   [Full Text] [Related]  

  • 8. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.
    Liu Y; Liu J; Xia H; Zhang X; Zou J; Fontes-Garfias CR; Weaver SC; Swanson KA; Cai H; Sarkar R; Chen W; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Xie X; Dormitzer PR; Shi PY
    N Engl J Med; 2021 Jul; 385(5):472-474. PubMed ID: 33979486
    [No Abstract]   [Full Text] [Related]  

  • 9. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
    Nemet I; Kliker L; Lustig Y; Zuckerman N; Erster O; Cohen C; Kreiss Y; Alroy-Preis S; Regev-Yochay G; Mendelson E; Mandelboim M
    N Engl J Med; 2022 Feb; 386(5):492-494. PubMed ID: 34965337
    [No Abstract]   [Full Text] [Related]  

  • 10. Neutralizing Activity of BNT162b2-Elicited Serum.
    Liu Y; Liu J; Xia H; Zhang X; Fontes-Garfias CR; Swanson KA; Cai H; Sarkar R; Chen W; Cutler M; Cooper D; Weaver SC; Muik A; Sahin U; Jansen KU; Xie X; Dormitzer PR; Shi PY
    N Engl J Med; 2021 Apr; 384(15):1466-1468. PubMed ID: 33684280
    [No Abstract]   [Full Text] [Related]  

  • 11. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.
    Shen X; Tang H; Pajon R; Smith G; Glenn GM; Shi W; Korber B; Montefiori DC
    N Engl J Med; 2021 Jun; 384(24):2352-2354. PubMed ID: 33826819
    [No Abstract]   [Full Text] [Related]  

  • 12. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
    Liu J; Liu Y; Xia H; Zou J; Weaver SC; Swanson KA; Cai H; Cutler M; Cooper D; Muik A; Jansen KU; Sahin U; Xie X; Dormitzer PR; Shi PY
    Nature; 2021 Aug; 596(7871):273-275. PubMed ID: 34111888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.
    Jalkanen P; Kolehmainen P; Häkkinen HK; Huttunen M; Tähtinen PA; Lundberg R; Maljanen S; Reinholm A; Tauriainen S; Pakkanen SH; Levonen I; Nousiainen A; Miller T; Välimaa H; Ivaska L; Pasternack A; Naves R; Ritvos O; Österlund P; Kuivanen S; Smura T; Hepojoki J; Vapalahti O; Lempainen J; Kakkola L; Kantele A; Julkunen I
    Nat Commun; 2021 Jun; 12(1):3991. PubMed ID: 34183681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms.
    Harrington P; de Lavallade H; Doores KJ; O'Reilly A; Seow J; Graham C; Lechmere T; Radia D; Dillon R; Shanmugharaj Y; Espehana A; Woodley C; Saunders J; Curto-Garcia N; O'Sullivan J; Raj K; Kordasti S; Malim MH; Harrison CN; McLornan DP
    Leukemia; 2021 Dec; 35(12):3573-3577. PubMed ID: 34023850
    [No Abstract]   [Full Text] [Related]  

  • 15. Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma.
    Wang Y; Ma Y; Xu Y; Liu J; Li X; Chen Y; Chen Y; Xie J; Xiao L; Xiang Z; Wu F; Huang J
    Emerg Microbes Infect; 2022 Dec; 11(1):424-427. PubMed ID: 35001836
    [No Abstract]   [Full Text] [Related]  

  • 16. Pfizer COVID vaccine protects against worrying coronavirus variants.
    Callaway E
    Nature; 2021 May; 593(7859):325-326. PubMed ID: 33963317
    [No Abstract]   [Full Text] [Related]  

  • 17. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
    Falsey AR; Frenck RW; Walsh EE; Kitchin N; Absalon J; Gurtman A; Lockhart S; Bailey R; Swanson KA; Xu X; Koury K; Kalina W; Cooper D; Zou J; Xie X; Xia H; Türeci Ö; Lagkadinou E; Tompkins KR; Shi PY; Jansen KU; Şahin U; Dormitzer PR; Gruber WC
    N Engl J Med; 2021 Oct; 385(17):1627-1629. PubMed ID: 34525276
    [No Abstract]   [Full Text] [Related]  

  • 18. Omicron likely to weaken COVID vaccine protection.
    Callaway E
    Nature; 2021 Dec; 600(7889):367-368. PubMed ID: 34880488
    [No Abstract]   [Full Text] [Related]  

  • 19. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.
    Wang GL; Wang ZY; Duan LJ; Meng QC; Jiang MD; Cao J; Yao L; Zhu KL; Cao WC; Ma MJ
    N Engl J Med; 2021 Jun; 384(24):2354-2356. PubMed ID: 33822491
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.